In focus · trending topic

IMC

11 stories · following the connections

Immuron’s Travelan® Sales Continue to Soar in Third Quarter of FY2018 in Australian & US Markets

By Nasdaq OMXApr 23, 2018, 1:30 PM UTC

Immuron Announces A$5.1M Private Placement to U.S. Fund

By Nasdaq OMXMar 13, 2018, 10:20 PM UTC

Immuron Reports Positive Results in NASH Clinical Trial

By Nasdaq OMXMar 7, 2018, 11:30 PM UTC

Travelan® Revenue Grows Significantly in US and Australia

By Nasdaq OMXFeb 16, 2018, 2:30 PM UTC

Natural Resources Canada Awards Contract to Innovation Metals Corp. and Metalysis for Research on the Production of Rare-Earth Oxides and Alloys

By Nasdaq OMXFeb 16, 2018, 1:00 PM UTC

Immuron Enrols First Patients in Clinical Study of IMM-529 for Treatment of Clostridium Difficile Infection (CDI)

By Nasdaq OMXJan 31, 2018, 2:30 PM UTC

Immuron to Receive $2.16M R&D Tax Concession Refund

By Nasdaq OMXJan 24, 2018, 2:30 PM UTC

CEO to Present on US Investor TV Show and at Biotech Conference

By Nasdaq OMXJan 10, 2018, 2:04 PM UTC